Mechanisms of Action Behind Advanced CSU Therapies

Segment summary: In this episode titled “Mechanisms of Action Behind Advanced CSU Therapies,” the panel dives into the underlying immunology of CSU and how each advanced therapy class intervenes in the disease pathway. The panel emphasizes that clinicians must confidently reassure patients that CSU is an autoimmune disease, not an allergy, a distinction considered foundational to patient education. Mechanistically, mast cell activation in CSU can arise from autoantibodies directed against IgE itself, against the IgE receptor on the mast cell surface, or against an as-yet-unidentified internal antigen, and unfortunately, there is no clinically useful biomarker to predict which pathway predominates in an individual patient.

Each advanced therapy class is then explained in turn. Omalizumab, an anti-IgE biologic, works by binding circulating IgE directly, making it particularly effective when autoantibody-driven IgE activity dominates, but less helpful when the receptor itself is the primary autoimmune target. Dupilumab, a biologic targeting the IL-4 receptor pathway, has a less clearly defined mechanism in CSU; possible explanations include shifting the immune response away from a Th2-skewed pattern, gradually lowering IgE levels over time, or directly blocking IL-4 receptors expressed on mast cells.

Finally, remibrutinib, an oral BTK inhibitor, works downstream of receptor activation, blocking the intracellular signaling enzyme mast cells require to degranulate regardless of which upstream trigger initiated the cascade, a mechanism described as the most intuitive of the three. It is compared to a master switch that shuts down the final common pathway leading to histamine release, offering a unifying rationale for its broad effectiveness across multiple disease drivers and a clear way to explain treatment choice to patients. In the next episode, “Trial Data and Safety of Remibrutinib for CSU,” the panel reviews pivotal trial results and addresses lingering safety questions around an oral BTK inhibitor’s labeled bleeding warning.